- Home
- CKPT vs PZC Comparison
CKPT vs PZC Comparison
Compare CKPT & PZC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- PZC
- Stock Information
- Founded
- CKPT 2014
- PZC 2002
- Country
- CKPT United States
- PZC United States
- Employees
- CKPT N/A
- PZC N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- PZC Investment Managers
- Sector
- CKPT Health Care
- PZC Finance
- Exchange
- CKPT Nasdaq
- PZC Nasdaq
- Market Cap
- CKPT 151.9M
- PZC 150.3M
- IPO Year
- CKPT 2017
- PZC N/A
- Fundamental
- Price
- CKPT $3.00
- PZC $6.71
- Analyst Decision
- CKPT Strong Buy
- PZC
- Analyst Count
- CKPT 2
- PZC 0
- Target Price
- CKPT $13.50
- PZC N/A
- AVG Volume (30 Days)
- CKPT 998.1K
- PZC 48.2K
- Earning Date
- CKPT 11-12-2024
- PZC 01-01-0001
- Dividend Yield
- CKPT N/A
- PZC 4.68%
- EPS Growth
- CKPT N/A
- PZC N/A
- EPS
- CKPT N/A
- PZC N/A
- Revenue
- CKPT $47,000.00
- PZC N/A
- Revenue This Year
- CKPT N/A
- PZC N/A
- Revenue Next Year
- CKPT $172,016.02
- PZC N/A
- P/E Ratio
- CKPT N/A
- PZC N/A
- Revenue Growth
- CKPT N/A
- PZC N/A
- 52 Week Low
- CKPT $1.38
- PZC $6.30
- 52 Week High
- CKPT $4.50
- PZC $8.20
- Technical
- Relative Strength Index (RSI)
- CKPT 38.29
- PZC 38.53
- Support Level
- CKPT $3.07
- PZC $6.62
- Resistance Level
- CKPT $3.42
- PZC $6.74
- Average True Range (ATR)
- CKPT 0.21
- PZC 0.08
- MACD
- CKPT -0.03
- PZC -0.00
- Stochastic Oscillator
- CKPT 4.94
- PZC 26.83
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About PZC PIMCO California Municipal Income Fund III of Beneficial Interest
PIMCO CA Muni Income Fund III operates as a closed-end management investment company. The investment objective of the fund is to seek to provide current income exempt from federal and California income tax. Its portfolio of investments includes investment in different sectors such as education, healthcare, industrial and others.